Marshall Wace, LLP Vectiv Bio Holding Ag Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

Shares

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	BUY	$7.34 - $9.15 $2.2 Million - $2.75 Million	300,000 Added 21.9%	1,669,656 $14.2 Million
Q4 2022 Feb 14, 2023	BUY	$7.79 - $8.98 $6.75 Million - $7.79 Million	867,000 Added 172.48%	1,369,656 $11.9 Million
Q2 2022 Aug 15, 2022	BUY	$4.2 - $6.55 $2.11 Million - $3.29 Million	502,656 New	502,656 $2.71 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.